Breve Curriculum

Dr. Francesco Demartis

già Researcher Associate, University of California, Berkeley

Membro della Società Italiana di Emostasi e Trombosi

Specialista in Ematologia Clinica

Master di II livello in Trombosi

Dirigente di I Livello

Agenzia Regionale Coagulopatie Congenite

Azienda Ospedaliera Universitaria

Careggi, Firenze

Pubblicazioni

 Books:

F.Demartis “HFR e trapianti di Midollo osseo”

(Edizioni il Melograno, Milano 1990).

F.Demartis (a cura di) “Princìpi di Etica Biomedica”

(Le Lettere, Firenze 1999).

F.Demartis (a cura di) II edizione, “Princìpi di Etica Biomedica”

(Le Lettere, Firenze, 2009).

 

F.Demartis, “Sulle Diverse Colpe dei Medici “ Feltrinelli 2012, Milano

F.Demartis  “Vivere l’emofilia” Carocci Editore, Roma 2015

  

Papers:

Herndier B.G.,F.Demartis, Shuman M.A., Levy J.A. Characterization of a Human Kaposi s Sarcoma cell line that induces angiogenic tumors in animals. (AIDS,8, 575/581,1994)

F.Demartis,R.Bok,M.Shuman Characterization of Integrins on a Kaposi s Sarcoma cell Line. (Biotec, vol 9,2, 141,1994)

F.Demartis,Choen R.L. R.Bok,M.Shuman Alterations in integrins expression on KS cell line transfected with CAT. (Biotec, vol 9,2,141, 1994) 

Frederick H. Lowy, F.Demartis,Paterson M.A., Klotzko A.J., Friedl B. Immortality Through the Fertility Clinic, (Cambridge Quarterly of Healthcare Ethics,4,375/386,1995)

F.Demartis Community and Healthcare (Bioethics Beyond Borders, University of California, Berkeley June 1995)  (Cambridge Quarterly of Healthcare Ethics)

F.Demartis “International Bioethics”, (Bioethics Beyond Borders, University of California, Berkeley June 1995)

F.Demartis “Community and Healthcare in the Italian Renaissance”, (Bioethics Beyond Borders, University of California, Berkeley June 1995)

F.Demartis, “Dall’Etica Medica alla Bioetica”, (Testimonianze, 391, 1997)

F.Demartis, ” Responsabilita’ in Campo Medico”, (Testimonianze, 397, 1998)

F.Demartis, “Mass pre-embryo adoption”, (Cambridge Quarterly of Healthcare Ethics, Vol 7, n° 1, 1998)

E. Zanon, A.Iorio, A.Rocino,  F.Demartis, L.Valdre’ (et al)

“Intracranial haemorrage in the Italian population of haemophilia patients with

and without inhibitors”

Haemophilia 2012  39-45

 

Demartis F., De Cristofaro R., Santagostino E. (et al)

“Analgesic effects  of High Intensity Laser Therapy (HILT) for chronic hemophilic artrhopathy :  a pilot study on safety , tolerability and clinical outcomes”.

Energy for Health, Vol 11, 2013

 

Kavakli K, Arkhammar P, Benson G, Chambost H, Demartis F, Rosholm A,

Interim results from the prospective observational study on Novoseven room temperature stable (VII25) in patients with hemophilia A or B. 

Journal Thrombosys Haemostasis 2014;12(Supll.1):63-4

 

Chambost H, Santagostino E, Laffan M, Kavakli K; The ONE Registry Steering Committee on behalf of the investigators.

 “Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry.”

Haemophilia. 2013 Jul;19(4):571-7. doi: 10.1111/hae.12140. Epub 2013 Apr 5 Collaborator

 

Gary Benson, Hervé Chambost,Francesco Demartis, Kaan Kavakli.

Benefit of Early Treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in Patients with Hemophilia A or B with Inhibitors: Subgroup Analysis from the Prospective, Post-authorization, Non-interventional SMART-7 Study

  

 

Kavakli, K; Demartis, F.; Karimi, M; Eshghi, P.; Chambost, Hervé;

Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: results of a multinational, prospective, observational study

Haemophilia July 2017

 

RECENT POSTERS :

 

Gary Benson, Hervé Chambost,Francesco Demartis, Kaan Kavakli.

Benefit of Early Treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in Patients with Hemophilia A or B with Inhibitors: Subgroup Analysis from the Prospective, Post-authorization, Non-interventional SMART-7 Study

ASH 2016 San Diego.

 

Kavakli K, Demartis F. Arkhammar P, Benson G.

Bleeding characteristics of patients with congenital hemophilia and inhibitors: data from a postmarketing study of recombinant activated factor VII (SMART-7)

WFH Orlando 2016: Haemophilia Volume 22, Issue S4, July 2016, Pages: 139–150

 

G. Benson, S. Benchikh el Fegoun, H. Chambost, F. Demartis M. Zak, K. Kavakli

The SMART-7 study: a design resulting in valuable results (EAHAD 2016)

 Haemophilia (2016), 22 (Suppl. 2), 112–116

 

Kavakli K, Demartis F. Arkhammar P, Benson G, Chambost H, Rosholm

A Safety of room temperature stable recombinant activated factor VII (VII25) in patients with haemophilia A or B with inhibitors: Results from the prospective, observational SMART-7 study (EAHAD 2016) Haemophilia (2016), 22 (Suppl. 2), 112–116

 

Kavakli K, Demartis F. Arkhammar P, Benson G, Chambost H, Rosholm A

Interim results from the prospective observational study on NovoSeven® room temperature stable (VII25) in patients with haemophilia A or B; (ISTH 2014 ; Milwakee)

 

F.Demartis, S.Milani: “Staging of Liver Fibrosis with non invasive methods in Haemophilic Patients infected by HCV” (Siset 2010 ; Bologna)

 

A.Peris, A.DiFilippo, F.Demartis,(et al.) “Large retroperitoneal bleeding in haemophilic recovered by damage control surgery and integrated therapies”(Pan European Haemophilia Meeting, Budapest 2009)